Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease

被引：8

作者：

Hsueh, W. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90024 USA

来源：

PHARMACOGENOMICS JOURNAL | 2006年 / 6卷 / 04期

关键词：

D O I：

10.1038/sj.tpj.6500383

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

[No abstract available]

引用

页码：222 / 224

页数：3

共 29 条

[1] Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies [J].

Alexander, GE ;

Chen, K ;

Pietrini, P ;

Rapoport, SI ;

Reiman, EM .

AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (05) :738-745

[2] Rosiglitazone reduces urinary albumin excretion in type II diabetes [J].

Bakris, G ;

Viberti, G ;

Weston, WM ;

Heise, M ;

Porter, LE ;

Freed, MI .

JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (01) :7-12

[3] Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype [J].

Craft, S ;

Asthana, S ;

Cook, DG ;

Baker, LD ;

Cherrier, M ;

Purganan, K ;

Wait, C ;

Petrova, A ;

Latendresse, S ;

Watson, GS ;

Newcomer, JW ;

Schellenberg, GD ;

Krohn, AJ .

PSYCHONEUROENDOCRINOLOGY, 2003, 28 (06) :809-822

[4] Insulin and neurodegenerative disease: shared and specific mechanisms [J].

Craft, S ;

Watson, GS .

LANCET NEUROLOGY, 2004, 3 (03) :169-178

[5] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[6] Stimulation of β-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling [J].

Gasparini, L ;

Gouras, GK ;

Wang, R ;

Gross, RS ;

Beal, MF ;

Greengard, P ;

Xu, HX .

JOURNAL OF NEUROSCIENCE, 2001, 21 (08) :2561-2570

[7] Muscle-specific Pparg deletion causes insulin resistance [J].

Hevener, AL ;

He, WM ;

Barak, Y ;

Le, J ;

Bandyopadhyay, G ;

Olson, P ;

Wilkes, J ;

Evans, RM ;

Olefsky, J .

NATURE MEDICINE, 2003, 9 (12) :1491-1497

[8] Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors [J].

Iwaki, M ;

Matsuda, M ;

Maeda, N ;

Funahashi, T ;

Matsuzawa, Y ;

Makishima, M ;

Shimomura, I .

DIABETES, 2003, 52 (07) :1655-1663

[9] The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles [J].

Janson, J ;

Ashley, RH ;

Harrison, D ;

McIntyre, S ;

Butler, PC .

DIABETES, 1999, 48 (03) :491-498

[10] Thiol reducing compounds prevent human amylin-evoked cytotoxicity [J].

Konarkowska, B ;

Aitken, JF ;

Kistler, J ;

Zhang, SP ;

Cooper, GJS .

FEBS JOURNAL, 2005, 272 (19) :4949-4959

← 1 2 3 →